Abstract
The human phagocytosis system represents a major immunological defense barrier. At the onset of bacterial sepsis the phagocytosis capacity of blood neutrophils markedly decreases to values below 30% of normal. Therefore it seems a reasonable therapeutic approach to support the phagocytosis system by an extracorporeal phagocytosis device. We demonstrate in vitro-data showing that phagocytosis of relevant amounts of pathogenic bacteria and fungi can be achieved in suitable bioreactor-systems. The human promyelocytic cell line HL-60 was differentiated towards neutrophils upon stimulation with all trans-retinoic acid (atRA). The phagocytosis index of stimulated HL-60 was higher than in normal peripheral blood neutrophils. The HL-60 phagocytosis among others comprises internalization of living and dead E.coli, Staphylococcus aureus and Candida albicans. Highly relevant concentrations of Candida albi-cans could be removed from cell culture-medium (2×105 C. alb./ml). Stimulated phagocytes can be separated by magnetic microbeads from inactive cells to increase the efficiency of the system. In conclusion phagocytosis assist seems to be an interesting approach to extracorporeal detoxification in sepsis and neutropenia lowering the microbial burden of the blood.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Stites DP, Terr AI (Eds.) (1991). Basic and clinical immunology.East Norwalk Appleton & Lange, 317.
Metchnikoff E (1884). Ueber eine Sprosspilzkrankheit der Daphnien: Beitrag zur Lehre ueber den Kampf der Phagozyten gegen Krankheiterreger. Arch path Anat Physiol 96, 177–195.
Schuster HP (1989). Clinical definition and incidence.In Sepsis. An interdisciplinary challenge. Reinhart K, Eyrich K (Eds.), Berlin, Springer Verlag, 1–6.
Lode H, Wagner J, Müller F, Hund M, Fangmann B, Löhr A (1989). Epidemiology, clinical course and prognosis of sepsis in 691 patients. In Sepsis. An interdisciplinary challenge. Reinhart K, Eyrich K (Eds.), Berlin, Springer Verlag, 7–22.
The Veterans Administration Systemic Sepsis Cooperative Study Group (1987). Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317, 659–665.
Inthorn D, Mühlbayer D (1992). Sepsisinduzierte EinschränkunggranulozytärerBakterizidiemechanismen. Abstract Wiener Intensivmedizinische Tage, FV 17.
Babcock GF, Rodeberg DA, White-Owen C (1994). Changes in neutrophil Junction following major trauma or thermal injury. Intensiv Care Med 20 (Suppl. 1), 5172.
Klastersky J, Zinner SH, Calandra T (1988). Empiric antimicrobial therapy for febrile granulocytopenic cancer patients.- Lessons from four EORTC trials. Europ J Cancer & Clin Oncol 24, S35–S45.
Fossat C, Stoppa AM, Sainty D et al (1990). G-CSF in vivo improves neutrophils bactericidal activity against Pseudomonas aeruginosa in cancer patients. Blood 76,144a.
Craven DE, Steger KA, Barat LM, Duncan RA (1992). Nosocomial pneumonia epidemiology and infection control. Int Care Med 18, 3–9.
Engelhardt D, Fuhr HG, Müller E, Mutters R, Ruckdeschel (1994). Nosokomiale Pneumonie. Stuttgart, New York, Thieme Verlag.
Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC (1991). Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 324, 429–436.
Saba TM (1993). Fibronectin and the reticuloendothelial system: Relationship to lung vascular failure during septic shock. In Pathophysiology of shock, sepsis, and organ failure. Schlag G, Redl H (Eds.), Berlin, New York, Springer Verlag, 724–746.
Tsakona CP, Khwaja A, Goldstone AH (1993). Does treatment with haematopoietic growth factors affect the incidence of bacteraemia in adult lymphoma transplant recipients Bone Marrow Transplant 11, 433–436
Kaben U, Uhlmann H, Westphal HJ, Schutt C, Skierlo P (1985). North American Blastomycosis in an African patient - clinical picture, treatment, immunological parameters. Mykosen 28, 585–594.
Marks DH, Medina F, Lee S, Blackmon A, Schuschereba ST (1988). Removal of bacteria from blood by charcoal hemoperfusion. Biomat Artif Cells Artif Organs 16, 135–140.
Mitzner S, Schneidewind J, Falkenhagen D, Loth F, Klinkmann H (1993). Extracorporeal endotoxin removal by immobilized polyethylenimine. Artif Organs 17, 775–781.
Kodama M, Aoki H, Tani T, Hanasawa K (1993). Hemoperfusion using a polymyxin B immobilized fiber column for the removal of endotoxin. In Bacterial endotoxin Recognition and effector mechanisms. Levin J, Alving CR, Munford RS, Stutz PL (Eds.), Elsevier Science Publishers BV, Amsterdam, 389–398.
Rozga J, Podesta L, Le Page E (1994). A bioartificial liver to treat severe acute liver failure. Ann Surg 219, 538–546.
Sussman NL, Gislason GT, Conlin CA, Kelly JH (1994). The Hepatix extracorporeal liver assist device: Initial clinical experience. Artif Organs 18, 390–396.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Mitzner, S. et al. (1997). In Vitro-Separation of Active Phagocytes for Temporary Extracorporeal Phagocytosis Assist by Magnetic Microbeads. In: Häfeli, U., Schütt, W., Teller, J., Zborowski, M. (eds) Scientific and Clinical Applications of Magnetic Carriers. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-6482-6_27
Download citation
DOI: https://doi.org/10.1007/978-1-4757-6482-6_27
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-3283-9
Online ISBN: 978-1-4757-6482-6
eBook Packages: Springer Book Archive